HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SNOA
Sonoma Pharmaceuticals, Inc.
There isn't enough reported data to score SNOA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SNOA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Weak | |
| Unavailable |
SNOA's revenue is currently strong, and its profitability is stable, but its cash flow is weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SNOA PE Valuation
SNOA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SNOA Forward outlook
There aren't enough analyst estimates for SNOA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SNOA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.91 | +$2.30 |
| Q2 2026 | -$1.22 | +$2.26 |
| Q1 2026 | -$1.89 | +$2.23 |
| Q4 2021 | -$54.20 | -$33.60 |
| Q3 2021 | -$54.40 | -$25.80 |
| Q2 2021 | -$52.40 | -$4.40 |
| Q1 2021 | -$39.40 | +$0.40 |
SNOA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SNOA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SNOA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | +28% |
| Q2 2026 | $6.4M | +60% |
| Q1 2026 | $5.6M | +48% |
| Q4 2025 | $4.3M | +22% |
| Q3 2025 | $5.6M | +57% |
| Q2 2025 | $4M | +18% |
| Q1 2025 | $3.8M | +9.2% |
| Q4 2024 | $3.6M | +14% |
SNOA's revenue has grown year over year for nine quarters in a row: $7M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4% | +10 points |
| Q2 2026 | -0.6% | +27 points |
| Q1 2026 | -6.3% | +11 points |
| Q4 2025 | -16% | +13 points |
| Q3 2025 | -6% | +18 points |
| Q2 2025 | -27% | +7.3 points |
| Q1 2025 | -17% | +24 points |
| Q4 2024 | -29% | -2 points |
SNOA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SNOA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SNOA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$778K | -$133K |
| Q2 2026 | -$651K | +$1.5M |
| Q1 2026 | -$548K | -$406K |
| Q4 2025 | -$811K | -244% |
| Q3 2025 | -$645K | -297% |
| Q2 2025 | -$2.1M | -$1.2M |
| Q1 2025 | -$142K | -192% |
| Q4 2024 | $563K | +$1.7M |
SNOA has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SNOA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SNOA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +1.1M shares |
| 1 year | +199% | +3.3M shares |
| 3 years | +4591% | +4.8M shares |
SNOA has 5M diluted shares, up 199% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SNOA Net Leverage
SNOA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SNOA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 18.2 | Oversold |
SNOA's weekly RSI is 38 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SNOA PE vs Healthcare Sector
SNOA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SNOA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.17 | 0% above |
| 20 week MA | $1.23 | 4.9% below |
| 50 week MA | $1.91 | 39% below |
| 100 week MA | $2.60 | 55% below |
| 200 week MA | $6.66 | 82% below |
SNOA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SNOA on returns for 2026, with the stronger performance.
SNOA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.2 | $163.6 | +85% |
| 2021 | $163.6 | $97.0 | -41% |
| 2022 | $97.0 | $23.0 | -76% |
| 2023 | $23.0 | $3.61 | -84% |
| 2024 | $3.61 | $2.75 | -24% |
| 2025 | $2.75 | $3.61 | +31% |
| 2026 YTD | $3.61 | $1.17 | -68% |
SNOA has finished lower in four of the last six years. It's down 68% so far in 2026.